AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
The Unified Acceleration Platform marks a paradigm shift in chronic disease research, redefining neurodegenerative, metabolic, and cardiovascular conditions as interconnected manifestations of systemic dysfunction—rather than isolated organ-specific diseases.
By integrating advances in molecular biology, epidemiology, systems medicine, and artificial intelligence, the platform identifies shared pathophysiological drivers, including disruptions in energy metabolism, chronic inflammation, mitochondrial dysfunction, and cellular senescence.
This systems-level approach accelerates the development of multi-indication therapies that target upstream disease mechanisms.
At ADA 2025, Biomed will present three scientific sessions featuring clinical and translational research that demonstrate mechanistic links between Alzheimer’s disease (AD), type 2 diabetes (T2DM), and obesity—specifically highlighting impaired insulin/IGF-1 signaling, oxidative stress, and chronic inflammation as converging pathways. These findings underpin Biomed’s integrated drug discovery strategy, which utilizes AI-driven target identification, cross-disease diagnostics, and molecular network modeling.
Biomed’s investigational drug candidates include:
• NA-831 – for Alzheimer’s disease (Phase 2/3)
• NA-911 – for stroke and ischemic brain injury (Phase 1/2)
• NA-931 – a novel quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity and metabolic diseases (Phase 2/3)
ADA 2025 presentations will include:
• NA-931: A Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight Without Muscle Loss
• Phase 2 Clinical Trials of NA-931 in Obese Subjects with At Least One Weight-Related Comorbidity
• Associations Between Alzheimer’s Disease and Obesity: Clinical Trials of NA-831 and NA-931
“The Unified Acceleration Platform has transformed how we discover and develop drug candidates across multiple chronic diseases,” said Dr. Lloyd Tran, CEO of Biomed Industries. “By identifying the biological links between conditions like Alzheimer’s and obesity—and leveraging advanced AI—we’re laying the foundation for therapies that target root causes and offer more effective, durable outcomes for some of the world’s most urgent health challenges.”
ABOUT BIOMED INDUSTRIES, INC.
Biomed Industries, Inc. is a pioneering biopharmaceutical company focused on developing transformative therapies for chronic and complex diseases. Its clinical pipeline includes investigational treatments for Alzheimer’s disease, major depressive disorder (MDD), obesity, diabetes, metabolic dysfunction-associated steatohepatitis (MASH), stroke, alcohol use disorder, and rare diseases including Rett syndrome.
Learn more at www.biomedind.com
About NA-931:
NA-931 is a first-in-class, orally active, small-molecule quadruple receptor agonist that targets IGF-1, GLP-1, GIP, and glucagon receptors. This multi-pathway approach restores metabolic balance and promotes meaningful weight loss without muscle wasting or severe side effects. In Phase 1 trials, NA-931 demonstrated potential benefits for both weight reduction and glycemic control in individuals with type 2 diabetes. Biomed recently completed a Phase 2 randomized, double-blind, placebo-controlled 13-week study in patients with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Topline results will be announced on June 20, 2025 at ADA 2025.
About NA-831:
NA-831 is an orally administered small molecule that promotes neurogenesis and exhibits neuroprotective effects. It is designed to restore memory and cognitive function in patients with early-stage Alzheimer’s disease. Phase 2 trials have demonstrated proof of efficacy and a favorable safety profile.
About NA-911:
NA-911 is a neuroprotective agent in development for ischemic stroke and hypoxic brain injury. A structural analogue of NA-931, it is currently in Phase 2 clinical trials. NA-911 demonstrates optimal efficacy when administered within 9–12 hours post-stroke, offering a significantly extended therapeutic window compared to current standards.
Michael Willis
Biomed Industries, Inc.
+1 800-824-5135
email us here
Visit us on social media:
LinkedIn
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
